This consensus definition aims to provide clarity for clinical trials, improve consistency in research, and guide treatment approaches and inform regulatory pathways. It represents a foundational step in addressing the unmet needs in TRBD and promoting the development of innovative therapeutic strategies. Future efforts will focus on adapting the definition to better align with real-world clinical challenges and optimize patient care.
Diego Hidalgo‐Mazzei, Michael Berk, Andrea Cipriani, Anthony J. Cleare, Arianna Di Florio, Daniel Dietch, John Geddes, Guy M. Goodwin, Heinz Grunze, Jeanie Hayes, I. Jones, Siegfried Kasper, Karine Macritchie, R. Hamish McAllister‐Williams, Richard Morriss, Sam Nayrouz, Sofia Pappa, Jair C. Soares, Daniel J. Smıth, Trisha Suppes, Peter S. Talbot, Eduard Vieta, Stuart Watson, Lakshmi N. Yatham, Andrew Young, Stokes Pra.
Roger S. McIntyre, Mohammad Alsuwaidan, Bernhard T. Baune, Michael Berk, Koen Demyttenaere, Joseph F. Goldberg, Philip Gorwood, Roger Ho, Siegfried Kasper, Sidney H. Kennedy, Josefina T Ly-Uson, Rodrigo B. Mansur, R. Hamish McAllister‐Williams, James W. Murrough, Charles B. Nemeroff, Andrew A. Nierenberg, Joshua D. Rosenblat, Gerard Sanacora, Alan F. Schatzberg, Richard C. Shelton, Stephen M. Stahl, Madhukar H. Trivedi, Eduard Vieta,
Willem A. Nolen, Rasmus Wentzer Licht, Allan H. Young, Gin S. Malhi, Mauricio Tohen, Eduard Vieta, Ralph Kupka, Carlos A. Zarate, René Ernst Nielsen, Ross J. Baldessarini, Emanuel Severus
Discussion(0)
No comments yet. Be the first to comment.